MaxCyte Inc. (MXCT)

Business: MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies.

IPO Date: 30-Jul-2021

Founder, Pres, CEO & Exec. Director: Mr. Douglas Arthur Doerfler

Chief Financial Officer: Mr. Ronald Evan Holtz CPA, Ph.D.

Listing: NASDAQ: MXCT

Country: United States

Headquarters: Gaithersburg, MD

Website: https://maxcyte.com

Market cap: $510.75 Mln

Revenue (TTM): $38.99 Mln

Earnings (TTM): $-16.04 Mln

Cash: $246.28 Mln

Total Debt: $13.25 Mln

Insider's Holding: 5.22%

Liquidity: Low

52 Week range: $3.36 - 17.44

Shares outstanding: 101,540,000

5 Years Aggregate:

• CFO: $-48.43 Mln
• EBITDA: $-57.31 Mln
• Net Profit: $-62.58 Mln